ReviewCNS drugs2019
Buprenorphine Treatment for Opioid Use Disorder: An Overview.
Review in CNS drugs, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 107 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
107 citing papers in PubMed, 2 syntheses or guidelines pooled it, 197 citations in OpenAlex.
- Meta-Analysis and Topological Perturbation in Interactomic Network for Antiopioid Addiction Drug Repurposing.Journal of chemical information and modeling · 2025Pooled it
- A Systematic Review of Opioid Use Disorder and Related Biomarkers.Frontiers in psychiatry · 2021Pooled it
- Community-level determinants of buprenorphine provider availability: A ZCTA-level (zip code tabulation area) analysis.Drug and alcohol dependence reports · 2026Article
- Exploring the addictive potential of α-methylfentanyl and acetyl-α-methylfentanyl in animal models.Psychopharmacology · 2026Article
- Article
- Reframing Buprenorphine as a Pharmacologic Modifier of Opioid-Induced Respiratory Depression in the Fentanyl Era.Pharmaceuticals (Basel, Switzerland) · 2026Article
- The association between the T allele in rs204076 and treatment retention in patients receiving medication for opioid use disorder.Scientific reports · 2026Article
- Bridging Gaps in Care: Evaluation of a Mobile Health Model Addressing Social Determinants and Harm Reduction in Eastern Puerto Rico.International journal of environmental research and public health · 2026Article
- Buprenorphine Microinduction Treatment in Tri-Diagnosis Patients with Opioid Use Disorder and Chronic Non-Cancerous Pain.Current pain and headache reports · 2026Review
- "This whole thing is relationship medicine": A qualitative analysis of mobile and street-delivered medication for opioid use disorder in King County, Washington, using RE-AIM.Research square · 2026Article
- State Prior Authorization Prohibitions and Buprenorphine Retention Among Privately Insured Patients.JAMA health forum · 2026Article
- Perioperative Management of Patients on Buprenorphine.Current pain and headache reports · 2026Review
- Medicaid Expansion and Buprenorphine Dispensing in Early vs Recent Expansion States.JAMA network open · 2026Article
- Initiation, retention, and discontinuation of extended-release buprenorphine (BUP-XR) for opioid dependence: A single-arm multi-site trial in Ukraine.The International journal on drug policy · 2026Article
- Article
- Buprenorphine enhancesJournal of oral microbiology · 2026Article
- Real-world effectiveness of medication-assisted treatment and psychotherapy for opioid use disorder: a national multi-health care organization analysis.Frontiers in psychiatry · 2026Article
- Article
- Clinical Responses to Cocaine-Positive Urine Drug Screens in Patients Receiving Chronic Opioid Therapy: A Four-Patient Case Series.Orthopedic reviews · 2026Article
- Buprenorphine Dispensing Following Medicaid Expansion Amid Unwinding in North Carolina.JAMA network open · 2025Article
47 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Opioid use disorder affects over 26 million individuals worldwide. There are currently three World Health Organization-recommended and US Food and Drug Administration-approved medication treatments for opioid use disorder: the full opioid agonist methadone, the opioid partial agonist buprenorphine, and the opioid receptor antagonist naltrexone. We provide a review of the use of buprenorphine for the treatment of opioid use disorder and discuss the barriers, challenges, risks, and efficacy of buprenorphine treatment vs. other treatments. Although evidence from numerous studies has shown buprenorphine to be effective for the treatment of opioid use disorder, a majority of patients with opioid use disorder do not receive buprenorphine, or any other medical treatment. We review the different formulations of buprenorphine, including newer long-acting injectable formulations that may decrease the risk of diversion and improve adherence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.